Australian drugmaker EvoGenix has entered into a technology collaboration agreement with CSL Limited, also based in Australia, to develop human antibody therapeutics.
CSL will have the right to commercialize the products, with EvoGenix to receive royalty payments as therapeutics emerging from the collaboration reach the market, the companies reported.
Under the agreement, EvoGenix will receive research payments to carry out work on CSL's products. Each project carries a success payment for achievement of project goals, as well as milestone payments as the product advances through the subsequent stages of clinical testing and regulatory approval.
"CSL has identified antibody therapeutics as a focus of its expanding product pipeline," said Andrew Cuthbertson, CSL's chief scientific officer. "We are delighted to access key technologies which can accelerate development of our antibodies as effective treatments through this collaboration."